Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 301–400 of 1,035
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Pochon, S., Tardy, I., Bussat, P., Bettinger, T., Brochot, J., von Wronski, M., Passantino, L., & Schneider, M. (2010) · Investigative Radiology · doi:10.1097/rli.0b013e3181c5927c · Cited by 266
The shunt problem: control of functional shunting in normal and tumour vasculature
Pries, A. R., Höpfner, M., le Noble, F., Dewhirst, M. W., & Secomb, T. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2895 · Cited by 265
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Gerstner, E. R., & Fine, R. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0677 · Cited by 265
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Kidoya, H., Ueno, M., Yamada, Y., Mochizuki, N., Nakata, M., Yano, T., Fujii, R., & Takakura, N. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601982 · Cited by 265
“Based on the diverse functions of VEGFs in blood vessel formation, the VEGF/VEGFR system has proved effective in the clinical management of cancer patients by negatively regulating angiogenesis (Ferrara and Alitalo, 1999; Jain, 2005).”
BackgroundOkkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264
“Mathematical Modeling and In Vitro Models of NP’s Intratumoral Distribution The intratumoral delivery of macromolecules and NP requires several steps in transport, including vascular transport, transvascular transport, interstitial transport, cellular binding, internalization and metabolism (Figure 1) [19].”
BackgroundInfluentialBone Pain in Cancer Patients: Mechanisms and Current Treatment
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236047 · Cited by 262
“Recruited vascular cells form an aberrant tumor vasculature characterized by increased permeability and expression of cell adhesion molecules (CAMs), which promote the intravasation of tumor cells [23].”
BackgroundHellberg, C., Östman, A., & Heldin, C.-H. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_7 · Cited by 259
“As a consequence of the poor perfusion and abnormal functions of tumor vessels, the delivery of nutrients and oxygen into the tumor is poor ( Jain 2005 ).”
BackgroundPassaro, D., Di Tullio, A., Abarrategi, A., Rouault-Pierre, K., Foster, K., Ariza-McNaughton, L., Montaner, B., Chakravarty, P., Bhaw, L., Diana, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.001 · Cited by 258
“This structurally aberrant network affects the local blood flow, metabolite exchange, and oxygenation, leading to poor drug delivery, increased tumor growth, and metastatic potential (Carmeliet and Jain, 2011a, 2011b; Jain, 2005).”
BackgroundCheckpoint inhibitor immunotherapy in kidney cancer
Xu, W., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 261
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Lin, F., Shelton, S. E., Espíndola, D., Rojas, J. D., Pinton, G., & Dayton, P. A. (2017) · Theranostics · doi:10.7150/thno.16899 · Cited by 260
Stimulus-responsive nanopreparations for tumor targeting
Zhu, L., & Torchilin, V. P. (2013) · Integrative Biology · doi:10.1039/c2ib20135f · Cited by 258
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
“For instance, different from what preclinical studies predicted, bevacizumab improves clinical results only/mostly when combined with chemotherapy, in part because it “normalizes” residual tumor vessels and improves drug delivery.(14,15) In contrast, RTKIs are capable of suppressing tumor growth as monotherapy,(2) lik…”
BackgroundResultInfluentialWhite, N. S., McDonald, C. R., Farid, N., Kuperman, J., Karow, D., Schenker-Ahmed, N. M., Bartsch, H., Rakow-Penner, R., Holland, D., Shabaik, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3534 · Cited by 255
“However, these agents decrease permeability of the blood– brain barrier and, therefore, decrease contrast enhancement and edema in patients with high-grade gliomas in a manner that may not correlate with actual tumor response—a phenomenon known as pseudoresponse (56).”
BackgroundAnticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
“This normalization involves the pruning and remodeling of the tumor vasculature so that it more closely resembles normal vasculature”
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
“…tumour drug delivery, the duration of the open window during antiangiogenesis treatment needs to be better defined by improving imaging techniques, which can measure the spatial and temporal changes in blood flow and other physiological parameters with higher resolution (Jain, 2005).”
BackgroundInfluentialPhase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hashizume, H., Falcón, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., & McDonald, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1977 · Cited by 251
Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation
Bentley, K., Gerhardt, H., & Bates, P. A. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.09.015 · Cited by 251
“In tumours this reduces drug delivery and increases metastatic potential (Koganehira et al., 2003; Jain, 2005).”
BackgroundTumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Plate, K. H., Scholz, A., & Dumont, D. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1066-5 · Cited by 251
“The concept of ‘‘vascular normalization’’ has been introduced by Jain [60].”
Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 252
“Also, one of the possible effects of the anti-angiogenic activity of metronomic chemotherapy might be on tumor vessel remodelling, the so called “vessel normalization” hypothesis (18).”
Silencing Of Circular RNA-ZNF609 Ameliorates Vascular Endothelial Dysfunction
Liu, C., Yao, M.-D., Li, C.-P., Shan, K., Yang, H., Wang, J.-J., Liu, B., Li, X.-M., Yao, J., Jiang, Q., et al. (2017) · Theranostics · doi:10.7150/thno.19353 · Cited by 251
“A single angiogenesis inhibitor may not suffice to combat against pathological angiogenesis [29].”
BackgroundBiomaterials tools to modulate the tumour microenvironment in immunotherapy
Chao, Y., & Liu, Z. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00004-6 · Cited by 245
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Sajja, H., East, M., Mao, H., Wang, Y., Nie, S., & Yang, L. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581066 · Cited by 250
“A normalization hypothesis was recently proposed that calls for administration of anti-angiogenic agents to remodel and normalize the existing tumor vasculature [92].”
BackgroundAngiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Madu, C. O., Wang, S., Madu, C. O., & Lu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.44313 · Cited by 249
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96582 · Cited by 239
“Tumor vascular normalization refers to a process in which the tumor vasculature is remodeled to more closely resemble that of normal tissue vessels, and increased vessel perfusion (IVP) is a critical component of this process (20, 24, 25).”
BackgroundBiological role of matrix stiffness in tumor growth and treatment
Deng, B., Zhao, Z., Kong, W., Han, C., Shen, X., & Zhou, C. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03768-y · Cited by 244
“In tumor tissue, newly sprouted blood vessels are crucial for tumor growth, and are more tortuous and immature than normal tissue [93].”
BackgroundInorganic nanoparticle-based contrast agents for molecular imaging
Cho, E. C., Glaus, C., Chen, J., Welch, M. J., & Xia, Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.004 · Cited by 247
Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis
Doyle, B., & Caplice, N. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.089 · Cited by 246
Integrin Targeted Therapeutics
Millard, M., Odde, S., & Neamati, N. (2011) · Theranostics · doi:10.7150/thno/v01p0154 · Cited by 245
“The resulting increase in tumor blood flow may explain the seemingly paradoxical potentiation in efficacy observed when anti-angiogenic agents are combined with standard chemotherapies [99].”
Qiu, G.-Z., Jin, M.-Z., Dai, J.-X., Sun, W., Feng, J.-H., & Jin, W.-L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.002 · Cited by 245
Wu, W., Luo, L., Wang, Y., Wu, Q., Dai, H.-B., Li, J.-S., Durkan, C., Wang, N., & Wang, G.-X. (2018) · Theranostics · doi:10.7150/thno.23459 · Cited by 246
Bockhorn, M., Jain, R. K., & Munn, L. L. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70140-7 · Cited by 244
Self-citationOtt, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
“Tumor vasculature is often markedly abnormal leading to a hypoxic and acidic microenvironment with high interstitial fluid pressure (41).”
BackgroundLee, S. L. C., Rouhi, P., Jensen, L. D., Zhang, D., Ji, H., Hauptmann, G., Ingham, P., & Cao, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909228106 · Cited by 240
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
Backer, M. V., Levashova, Z., Patel, V., Jehning, B. T., Claffey, K., Blankenberg, F. G., & Backer, J. M. (2007) · Nature Medicine · doi:10.1038/nm1522 · Cited by 243
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
Barzegar Behrooz, A., Talaie, Z., Jusheghani, F., Łos, M. J., Klonisch, T., & Ghavami, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031353 · Cited by 240
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
“Furthermore, the anti-angiogenic vessel pruning strategy can effectively improve the potency of chemotherapy in several ways, for example, through the partial normalization of the tumor-associated vasculature by differentiation between the tumor-associated vasculature and tumor cells and their selective targeting, imp…”
BackgroundInfluentialLammers, T., Subr, V., Ulbrich, K., Peschke, P., Huber, P. E., Hennink, W. E., & Storm, G. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.040 · Cited by 240
“combination of P-Gem and P-Dox, which hints towards an enhanced ‘vessel normalization’ in tumors treated with targeted therapeutics [34,35].”
BackgroundImproving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin
Tang, N., Du, G., Wang, N., Liu, C., Hang, H., & Liang, W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm027 · Cited by 239
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
Greish, K., Nehoff, H., Parayath, N., Domanovitch, L., & Taurin, S. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s47129 · Cited by 238
“17 Although normalization of lymphatic vessels may appear to be a suitable method for decreasing IFP, pursuit of this technique is likely to produce unfavorable results and cause more damage than what would be observed in tissues with compressed lymphatics.”
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 238
Ejigah, V., Owoseni, O., Bataille-Backer, P., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 234
“Second, rapid metabolism in tumor cells leads to a high demand for nutrients and oxygen, which drives angiogenesis at high rates and prevents adequate vessel maturation [22].”
BackgroundGlioblastoma Multiforme Therapy and Mechanisms of Resistance
Ramirez, Y., Weatherbee, J., Wheelhouse, R., & Ross, A. (2013) · Pharmaceuticals · doi:10.3390/ph6121475 · Cited by 236
“Researchers are currently pursuing compounds that normalize tumor vasculature to disrupt tumor growth and enhance drug delivery [95].”
BackgroundTargeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle
Arvizo, R. R., Saha, S., Wang, E., Robertson, J. D., Bhattacharya, R., & Mukherjee, P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214547110 · Cited by 237
“Since HB–GFs are critically important for angiogenesis and epithelial–mesenchymal transition (EMT), a mechanism that confers metastatic potential to tumor cells, AuNPs may find wide applications as therapeutic agents in angiogenesisdependent disorders and in preventing tumor growth and metastasis in cancer (4).”
BackgroundInterstitial fluid flow in cancer: implications for disease progression and treatment
Munson, J., & Shieh, A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s65444 · Cited by 235
Toledo, B., Zhu Chen, L., Paniagua-Sancho, M., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01559-0 · Cited by 226
“However, the precise mechanisms and origin of macrophages remain unclear [9, 10].”
BackgroundEvading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
“owever, the constraints defined by the ability of tumor cells to xpress, from a limited set of endogenous pro-angiogenic factors, he angiogenic “bottleneck” constitutes a distinct and important election pressure. For evolving tumors, alternative expression of ngiogenic factors from a limited set of proteins is a relat…”
Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications
Wang, Z., Jin, A., Yang, Z., & Huang, W. (2023) · ACS Nano · doi:10.1021/acsnano.3c02303 · Cited by 229
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Antiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Hypoxia-Inducible Factor as an Angiogenic Master Switch
Hashimoto, T., & Shibasaki, F. (2015) · Frontiers in Pediatrics · doi:10.3389/fped.2015.00033 · Cited by 231
Hypoxia and acidosis: immune suppressors and therapeutic targets
Damgaci, S., Ibrahim‐Hashim, A., Enriquez‐Navas, P. M., Pilon‐Thomas, S., Guvenis, A., & Gillies, R. J. (2018) · Immunology · doi:10.1111/imm.12917 · Cited by 231
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
“Because these anti-angiogenic inhibitors are not tumor specific, successful clinical implementation will most likely consist of the use of drug doses/scheduling aiming at vessel normalization, promoting formation of functional vessels to improve drug delivery (172), or in their combination with other therapies, rather…”
BackgroundMeng, X., Zhang, J., Sun, Z., Zhou, L., Deng, G., Li, S., Li, W., Gong, P., & Cai, L. (2018) · Theranostics · doi:10.7150/thno.26607 · Cited by 230
“Hypoxia is a common characteristic of solid tumors [1-3].”
BackgroundWu, M., Frieboes, H. B., McDougall, S. R., Chaplain, M. A. J., Cristini, V., & Lowengrub, J. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.11.031 · Cited by 229
“This has led to the concept of vascular normalization to reduce IFP and to decrease transport barriers to improve drug penetration into tumors (Jain, 2001, 2005b; Tong et al., 2004; Jain et al., 2007).”
BackgroundPredicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
“However, there is evidence to suggest that the maximum tolerated dose of anti-angiogenic agents is not necessarily the most effectiv”
BackgroundHori, S. S., & Gambhir, S. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003110 · Cited by 227
“Each influx is a function of (i) the fraction of shed biomarker entering tumor vasculature, fPL,T, or healthy vasculature, fPL,H, which may differ because of the abnormal leakiness and dilation of tumor blood vessels (11) and the extent of biomarker degradation in the tumor microenvironment; (ii) the shedding rates of…”
BackgroundPiao, Y., Liang, J., Holmes, L., Zurita, A. J., Henry, V., Heymach, J. V., & de Groot, J. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos158 · Cited by 227
“In the early phases of antiangiogenic therapy, tumor oxygenation improves through the process of vascular normalization.(7) Corresponding Author: John de Groot, Unit 431, Department of”
BackgroundKim, S., Chung, M., Ahn, J., Lee, S., & Jeon, N. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00910g · Cited by 227
Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications
Uthaman, S., Huh, K. M., & Park, I.-K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0132-z · Cited by 227
Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 224
“1,17,18 Ang1 and Ang2 regulate vascular maturation and integrity during development; however, their effects on normalization of tumor vessels are not known.”
BackgroundMethodInfluentialHypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells
Donato, C., Kunz, L., Castro-Giner, F., Paasinen-Sohns, A., Strittmatter, K., Szczerba, B. M., Scherrer, R., Di Maggio, N., Heusermann, W., Biehlmaier, O., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108105 · Cited by 224
“…that a large body of literature has also high-lighted a vascular normalization effect for anti-VEGFA therapies as a function of therapy dosage and schedule (Jain, 2005, 2013), possibly influenced by tumor-intrinsic characteristics such as the extent and frequency of hypervascularized areas.”
Forty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J., D’Amato, R. J., D’Amore, P. A., Ingber, D. E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 223
Dong, X., Liu, H.-J., Feng, H.-Y., Yang, S.-C., Liu, X.-L., Lai, X., Lu, Q., Lovell, J. F., Chen, H.-Z., & Fang, C. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04236 · Cited by 223
Tumor radiation response enhancement by acoustical stimulation of the vasculature
Czarnota, G. J., Karshafian, R., Burns, P. N., Wong, S., Al Mahrouki, A., Lee, J. W., Caissie, A., Tran, W., Kim, C., Furukawa, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200053109 · Cited by 221
“Antiangiogenic treatments are believed to result in vascular normalization (25) through the “pruning” of cancer-related abnormal blood vessels.”
BackgroundIwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
“Finally, it has been suggested that anti-VEGF-mediated tumor vascular normalization may improve the delivery of cytotoxic drugs by decreasing tumor interstitial pressure thereby providing a rationale for combination therapy.(22) Thus, for optimizing regimens for glioblastoma, it may still be useful to identify VEGF/VE…”
BackgroundResultExtracellular Matrix, a Hard Player in Angiogenesis
Mongiat, M., Andreuzzi, E., Tarticchio, G., & Paulitti, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111822 · Cited by 223
“The altered vasculature not only represents an important root for metastatic spreading, but also affects the delivery of chemotherapy drugs [19,20].”
BackgroundMaione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F., & Giraudo, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36308 · Cited by 219
“A growing body of evidence implicates increased pericyte coverage, together with the reduction in blood vessel density and tortuosity, as a key property of tumor vessel normalization, a process occurring in response to certain antiangiogenic therapies that renders the tumor vasculature more efficient in delivering oxy…”
BackgroundResultInfluentialKunnumakkara, A. B., Diagaradjane, P., Guha, S., Deorukhkar, A., Shentu, S., Aggarwal, B. B., & Krishnan, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4722 · Cited by 217
Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 217
Zhou, Q., Dong, C., Fan, W., Jiang, H., Xiang, J., Qiu, N., Piao, Y., Xie, T., Luo, Y., Li, Z., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119902 · Cited by 218
Nakamura, K., Taguchi, E., Miura, T., Yamamoto, A., Takahashi, K., Bichat, F., Guilbaud, N., Hasegawa, K., Kubo, K., Fujiwara, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4290 · Cited by 207
“An attractive hypothesis recently advanced by Jain (40) proposes that some antiangiogenic agents could inhibit both new tumor vessel formation (neoangiogenesis) and transiently ‘‘normalize’’ the abnormal structure and function of tumor vasculature to enhance oxygen permeation and drug delivery.”
BackgroundCurrent research trends of nanomedicines
Liu, Q., Zou, J., Chen, Z., He, W., & Wu, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.018 · Cited by 213
“The tumor vascular system is distinguished from normal blood vessels by complicated, heterogeneous leaky vessels with heterogeneous blood flow 211,212 , which can promote passive tumor targeting and accumulation of nanocarriers based on the EPR effect 213,214 .”
BackgroundTargeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
“Secondly, the reduction of the fibrotic content, which decompresses the intratumoral vasculature, creates a window for the second-wave nanotherapy (9,34).”
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
“Unlike growing embryonic tissues, fast-growing tumor tissues promote the formation of primitive, leaky, hemorrhagic, and disorganized vasculatures, which are poorly perfused with oxygenated blood [11].”
BackgroundVessel abnormalization: another hallmark of cancer?
De Bock, K., Cauwenberghs, S., & Carmeliet, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.008 · Cited by 213
“These abnormal tumor vessels are characterized by a mal-shaped, irregular, disorganized and tortuous architecture with a highly dysfunctional and leaky endothelial cell (EC) layer [1,3].”
BackgroundInfluentialBranching morphogenesis and antiangiogenesis candidates: tip cells lead the way
Carmeliet, P., De Smet, F., Loges, S., & Mazzone, M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.64 · Cited by 212
SuperTarget goes quantitative: update on drug-target interactions
Hecker, N., Ahmed, J., von Eichborn, J., Dunkel, M., Macha, K., Eckert, A., Gilson, M. K., Bourne, P. E., & Preissner, R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr912 · Cited by 213
Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 212
Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Shanmugam, M. K., Warrier, S., Kumar, A. P., Sethi, G., & Arfuso, F. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666170713094319 · Cited by 213
Inflammatory Mechanisms of HCC Development
Refolo, M. G., Messa, C., Guerra, V., Carr, B. I., & D’Alessandro, R. (2020) · Cancers · doi:10.3390/cancers12030641 · Cited by 212
“In particular there is an upregulation of VEGF which exerts its action at the level of hematopoietic stem cells and liver endothelial cells, which respond by forming new vessels that compensate for the lack of oxygen and nutrients necessary for tumor growth [71,72].”
BackgroundBreast cancer models: Engineering the tumor microenvironment
Bahcecioglu, G., Basara, G., Ellis, B. W., Ren, X., & Zorlutuna, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.006 · Cited by 213
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
“The structural abnormalities of the vasculature alter permeability and tumor perfusion, and cause high interstitial fluid pressure”
BackgroundAngiogenesis and vascular remodelling in normal and cancerous tissues
Owen, M. R., Alarcón, T., Maini, P. K., & Byrne, H. M. (2009) · Journal of Mathematical Biology · doi:10.1007/s00285-008-0213-z · Cited by 211
“The basic framework was introduced in [4] and has since been extended to account for several features, including active cell movement [14], vessel co-option and dematuration and the effect of combination therapy [27].”
BackgroundInfluentialTWEAK/Fn14 pathway: an immunological switch for shaping tissue responses
Burkly, L. C., Michaelson, J. S., & Zheng, T. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01054.x · Cited by 208
Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Willers, H., Azzoli, C. G., Santivasi, W. L., & Xia, F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318292e4e3 · Cited by 208
Combinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207
Self-Healing Materials Systems: Overview of Major Approaches and Recent Developed Technologies
Aïssa, B., Therriault, D., Haddad, E., & Jamroz, W. (2012) · Advances in Materials Science and Engineering · doi:10.1155/2012/854203 · Cited by 206
“As reported by the paper of Murphy and Wudl [55], complex microvascular networks are widely observed in biological systems, such as leaf venation [99–102] and blood vascularisation [103–105].”
BackgroundThe interplay between macrophages and angiogenesis in development, tissue injury and regeneration
Nucera, S., Biziato, D., & De Palma, M. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103227sn · Cited by 207
“JAIN RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.”
BackgroundInfluential
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.